
==== Front
Nucleic Acids ResNucleic Acids ResnarNucleic Acids ResearchNucleic Acids Research0305-10481362-4962Oxford University Press 1715107410.1093/nar/gkl853ArticlesPharmGED: Pharmacogenetic Effect Database Zheng C. J. 12Han L. Y. 12Xie B. 12Liew C. Y. 12Ong S. 12Cui J. 12Zhang H. L. 12Tang Z. Q. 12Gan S. H. 12Jiang L. 12Chen Y. Z. 12*1Department of Pharmacy, Bioinformatics and Drug Design Group, National University of SingaporeBlk S16, Level 8, 3 Science Drive 2, Singapore 1175432Department of Computational Science, Bioinformatics and Drug Design Group, National University of SingaporeBlk S16, Level 8, 3 Science Drive 2, Singapore 117543*To whom correspondence should be addressed. Tel: +65 6516 6877; Fax: +65 6774 6756; Email: phacyz@nus.edu.sg1 2007 6 12 2006 06 12 2006 35 Database issue D794 D799 15 8 2006 10 10 2006 10 10 2006 © 2006 The Author(s)2006This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Prediction and elucidation of pharmacogenetic effects is important for facilitating the development of personalized medicines. Knowledge of polymorphism-induced and other types of drug-response variations is needed for facilitating such studies. Although databases of pharmacogenetic knowledge, polymorphism and toxicogenomic information have appeared, some of the relevant data are provided in separate web-pages and in terms of relatively long descriptions quoted from literatures. To facilitate easy and quick assessment of the relevant information, it is helpful to develop databases that provide all of the information related to a pharmacogenetic effect in the same web-page and in brief descriptions. We developed a database, Pharmacogenetic Effect Database (PharmGED), for providing sequence, function, polymorphism, affected drugs and pharmacogenetic effects. PharmGED can be accessed at  free of charge for academic use. It currently contains 1825 entries covering 108 disease conditions, 266 distinct proteins, 693 polymorphisms, 414 drugs/ligands cited from 856 references.
==== Body
INTRODUCTION
Individual response to drugs often differs significantly and these drug-response variations are frequently associated with polymorphisms of pharmacologically related proteins (1–5). Pharmacogenetic study of these proteins and their regulatory sites is important for the understanding of molecular mechanism of drug responses and for the development of personalized medicines (1,6–9). Resources that provide information about molecular mechanism of drug-response variations are useful for facilitating pharmacogenomics study and the development of personalized medicine (10). There have been calls and efforts for developing such resources (11) and the related informatics tools (12,13). A number of freely accessible web-based resources have been developed for providing information about genetic and clinical pharmacogenetic information (14), polymorphisms in drug-related proteins (15–20) and toxicogenomics data (21).

Although pharmacogenetic knowledge, polymorphism and toxicogenomic information are provided in these databases, some of the reported pharmacogetic effects are given in web-pages separate from that of other important information such as protein and drug information, and are often given by relatively long descriptions quoted from literatures. To facilitate easy and quick assessment of the relevant information, it is helpful to develop databases that provide all the information related to a pharmacogenetic effect in the same web-page. We developed Pharmacogenetic Effect Database (PharmGED) with the aim to provide the information about the effects of a particular protein polymorphism, non-coding region mutation, splicing alteration or expression variation on the response of a particular drug. It currently contains 1825 entries covering 108 disease conditions, 266 distinct proteins, 693 polymorphisms, 414 drugs/ligands cited from 856 references.

DATABASE STRUCTURE AND ACCESS
PharmGED has a web interface at . The entries of this database were derived from a comprehensive search of published literatures (via Medline) by using a similar search and evaluation procedure as we have used for developing other databases of drug-related proteins (15–18). Entries of this database are searchable by several methods. These methods include the search of protein name, drug/ligand name, disease name (extracted from the related terms described in the relevant publications) and drug class (derived based on the related terms described in the relevant publications). Full list of protein names, drug/ligand names, disease names and drug classes are separately provided in the PharmGED main web-page for facilitating the search of particular entries.

Moreover, keyword-based text search is also supported. The search is case insensitive and wildcards are supported. In a query, a user can specify full name or any part of the name in a text field. Wild character of ‘*’ and ‘?’ is allowed in text field. Here, ‘?’ represents any single character and ‘*’ represents a string of characters of any length. For example, input of ‘dehydrogenase’ in the field of protein/gene name enables the finding of all entries containing ‘dehydrogenase’ in the protein name, such as 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Alcohol dehydrogenase 1B, Alcohol dehydrogenase 1C, Fatty aldehyde dehydrogenase, Glucose-6-phosphate 1-dehydrogenase, NAD(P)H dehydrogenase (quinone) 1, etc. On the other hand, input of Fatty*dehydrogenase enables the finding of all dehydrogenases whose names start with ‘Fatty’.

The result of a typical search is illustrated in Figure 1. In this interface, all entries that satisfy the specified search criteria are listed along with protein name, polymorphism rules, drug/ligand name, drug classification, disease name and links to other related entries in this database. More detailed information of an entry can be obtained by clicking the corresponding protein name. The result is displayed in an interface shown in Figure 2. From this interface, one finds the accession number, name, sequence and function of protein, pharmacogenetic polymorphism, affected drugs and drug class, corresponding disease condition and pharmacogenetic effect. Moreover, the information about the related references and links to the literature database PUBMED (22) is also provided.

Figure 1 The interface displaying a search result on PharmGED. All entries that satisfy the specified search criteria are listed along with protein name, polymorphism rules, drug/ligand name, drug classification, disease name and links to other related entries in this database.

Figure 2 Interface displaying the detailed information of an entry in PharmGED.

POTENTIAL APPLICATIONS
Established links between polymorphisms of drug-related proteins and individual drug responses have been used in combination with genetic studies as indicators for predicting individual variations of drug response (23–27). Based on the statistical analysis of the data of polymorphisms and variation of drug response of the participating patients, simple rules may be derived in some cases for predicting individual variations of drug response from polymorphism data (23,24,26,28,29). These simple rules may be collected and used for developing a computer prediction system in a fashion similar to that of the HIV drug-resistant genotype interpretation systems (30).

Table 1 gives examples of the drug-related proteins in PharmGED with available information about pharmacogenetic polymorphism and drug-response variation from which a reasonably accurate rule have been derived in the literature for predicting responses to a specific drug or drug group. The reported percentage of patients who have a polymorphism and showed the expected effect is also given. Based on the test of the patients described in these reports, most of these rules are capable of predicting drug responses at success rates of 50–100%, which are not too much lower than and in many cases comparable to the accuracies of 81–97% for predicting HIV drug resistance mutations from the HIV-resistant genotype interpretation systems (30). This suggests that these simple rules have certain level of capacity for facilitating the prediction of pharmacogenetic effects and they may be used as the basis for developing more sophisticated interpretation systems similar to those of the HIV-resistant genotype interpretation systems (30).

Table 1 Prediction of specific drug responses from the polymorphisms of ADME-associated proteins by using simple rules

Protein	Drugs and treatment/action	Drug responses	Polymorphism rules and year of report	Number of patients with polymorphism	Reported percentage of patients who have a polymorphism and showed the expected effect	
Cytochrome P450 1A2	Antipsychotic agents for schizophrenia patients	Tardive dyskinesia	Bsp120I (C→A) polymorphism in CYP1A2 gene, 2000 (38)	85	69	
Cytochrome P450 2D6	Neuroleptic agents for chronic schizophrenic patients	Tardive dyskinesia	CYP2D6*4 genotype, 1998 (39)	13	81	
UDP-glucuronysltransferase	Capecitabine/irinotecan for the treatment of metastatic colorectal cancer	Greater antitumor response with low toxicity	UGT1A7*2/*2 genotype, 2005 (27)	6	100	
			UGT1A7*3/*3 genotype, 2005 (27)	7	100	
UDP-glucuronysltransferase I	Tranilast for the prevention of restenosis following coronary revascularization	Hyperbilirubinemia	Homozygosity for a (TA)7-repeat element within the promotor region of UGT1A1 gene, 2004 (23)	146	40	
N-acetyltransferase 2	Isoniazid for the prophylaxis and treatment of tuberculosis	ADRs such as peripheral neuritis, fever and hepatic toxicity	SA type (NAT2*6/*6, NAT2*6/*7 and NAT2*7/*7), 2002 (25)	6	83	
Tryptophan hydroxylase	Fluvoxamine for the treatment of depression	Antidepressant response	A218C A/C phenotypes, 2001 (40)	107	76	
			A218C C/C phenotypes, 2001 (40)	70	81	
			A218C A/A phenotypes, 2001 (40)	40	65	
Norepinephrine transporter	Milnacipran for the treatment of depression	Antidepressant response	T allele of the NET T182C polymorphism, 2004 (26)	50	72	
Serotonin transporter	Serotonin reuptake inhibitors for the treatment of depression	Antidepressant response	s/s genotype of serotonin transporter gene promoter region, 2000–2004 (1,2,41,42)	11–72	54% at sixth week	
			s/l genotype of serotonin transporter gene promoter region, 2000–2004 (1,2,41,42)	2–47	55% at sixth week	
			l/l genotype of serotonin transporter gene promoter region, 2000–2004 (1,2,41,42)	4–16	48% at sixth week	
Multidrug resistance-associated protein 1	Epileptic drugs for the treatment of epilepsy	Drug-resistant epilepsy	ABCB1 C3435T C/C genotype, 2003 (43)	73	75	
			ABCB1 C3435T C/T genotype, 2003 (43)	169	63	
			ABCB1 C3435T T/T genotype, 2003 (43)	73	53	
Multidrug resistance-associated protein 1	Combination therapy of nelfinavir, efavirenz and nucleoside reverse transcriptase inhibitors for HIV-1 infected children	Virologic response by week 8	MDR1 C3435T C/C genotype, 2005 (44)	31	59	
			MDR1 C3435T C/T genotype, 2005 (44)	33	91	
PharmGED and other databases (14–21) can be potentially used for facilitating the generation of these rules. For instance, one entry of PharmGED describes that patients using classical neuropleptic such as fluphenazine, haloperidol have a higher incidence (81%) of Tardive dyskinesia if they are of the genotype CYP2D6*4. The corresponding polymorphism can be obtained from a link provided in the database. These data combined with other information in PharmaGED can be used to generate the rule for detecting this pharmacogenetic effect described in Table 1. In a second example, another entry of PharmGED describes that the polymorphism C3435T (Ile1145Ile) of protein MDR1-3435 variant is associated with different virologic response of nelfinavir in HIV-1 infected children. Fifty-nine percent of the 31 C/C genotype and 91% of the 33 C/T genotype show virologic response at eighth week, respectively. These data can then be used to generate the rule for this pharmacogenetic effect as described in Table 1.

CONCLUDING REMARKS
Knowledge about protein polymorphisms and drug responses appears to have reached a meaningful level for facilitating pharmacogenetic study and for predicting various types of individual variations of drug responses. Specialized pharmacogenetics databases serve as convenient resources for obtaining the relevant information. With the rapid development of genomics (31), pharmacokinetics (32–35) and pharmacogenomics (6,8,9), more information about drug-related proteins, polymorphisms and variations of drug responses are expected to become available. Moreover, progress in the study of proteomics (36) and pathways (37) related to drug-related proteins will further facilitate our understanding of the mechanism of individual variations in drug response.

This work was supported in part by grants from Singapore ARF R-151-000-031-112. The Open Access publication charges for this article were waived by Oxford University Press.

Conflict of interest statement. None declared.
==== Refs
REFERENCES
1 Evans W.E.  Relling M.V.   Moving towards individualized medicine with pharmacogenomics Nature 2004 429 464 468 15164072 
2 Lindpaintner K.   Pharmacogenetics and the future of medical practice J. Mol. Med. 2003 81 141 153 12682723 
3 Marzolini C.  Paus E.  Buclin T.  Kim R.B.   Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance Clin. Pharmacol. Ther. 2004 75 13 33 14749689 
4 Evans W.E.  Hon Y.Y.  Bomgaars L.  Coutre S.  Holdsworth M.  Janco R.  Kalwinsky D.  Keller F.  Khatib Z.  Margolin J.    Preponderance of thiopurine S -methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine J. Clin. Oncol. 2001 19 2293 2301 11304783 
5 Marshall A.   Laying the foundations for personalized medicines Nat. Biotechnol. 1997 15 954 957 9335043 
6 Altman R.B.  Klein T.E.   Challenges for biomedical informatics and pharmacogenomics Annu. Rev. Pharmacol. Toxicol. 2002 42 113 133 11807167 
7 Kalow W.   Pharmacogenetics, pharmacogenomics, and pharmacobiology Clin. Pharmacol. Ther. 2001 70 1 4 11452237 
8 Marshall A.   Getting the right drug into the right patient Nat. Biotechnol. 1997 15 1249 1252 9359105 
9 Nicholls H.   Improving drug response with pharmacogenomics Drug Discov. Today 2003 8 281 282 12654535 
10 Zheng C.J.  Sun L.Z.  Han L.Y.  Ji Z.L.  Chen X.  Chen Y.Z.   Drug ADME-associated protein database as a resource for facilitating pharmacogenomics research Drug Dev. Res. 2004 62 134 142 
11 Gurwitz D.  Lunshof J.E.  Altman R.B.   A call for the creation of personalized medicine databases Nature Rev. Drug Discov. 2006 5 23 26 16374513 
12 Vyas H.  Summers R.   An information-driven approach to pharmacogenomics Pharmacogenomics 2005 6 473 480 16013997 
13 Freimuth R.R.  Stormo G.D.  McLeod H.L.   PolyMAPr: programs for polymorphism database mining, annotation, and functional analysis Hum. Mutat. 2005 25 110 117 15643605 
14 Klein T.E.  Chang J.T.  Cho M.K.  Easton K.L.  Fergerson R.  Hewett M.  Lin Z.  Liu Y.  Liu S.  Oliver D.E.    Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base Pharmacogenomics J. 2001 1 167 170 11908751 
15 Ji Z.L.  Han L.Y.  Yap C.W.  Sun L.Z.  Chen X.  Chen Y.Z.   Drug Adverse Reaction Target Database (DART): proteins related to adverse drug reactions Drug Saf. 2003 26 685 690 12862503 
16 Ji Z.L.  Sun L.Z.  Chen X.  Zheng C.J.  Yao L.X.  Han L.Y.  Cao Z.W.  Wang J.F.  Yeo W.K.  Cai C.Z.    Internet resources for proteins associated with drug therapeutic effects, adverse reactions and ADME Drug Discov. Today 2003 8 526 529 12821296 
17 Sun L.Z.  Ji Z.L.  Chen X.  Wang J.F.  Chen Y.Z.   ADME-AP: a database of ADME associated proteins Bioinformatics 2002 18 1699 1700 12490461 
18 Chen X.  Ji Z.L.  Chen Y.Z.   TTD: Therapeutic Target Database Nucleic Acids Res. 2002 30 412 415 11752352 
19 Ozawa N.  Shimizu T.  Morita R.  Yokono Y.  Ochiai T.  Munesada K.  Ohashi A.  Aida Y.  Hama Y.  Taki K.    Transporter database, TP-Search: a web-accessible comprehensive database for research in pharmacokinetics of drugs Pharm. Res. 2004 21 2133 2134 15587938 
20 Iida A.  Saito S.  Sekine A.  Takahashi A.  Kamatani N.  Nakamura Y.   Japanese single nucleotide polymorphism database for 267 possible drug-related genes Cancer Sci. 2006 97 16 24 16367916 
21 Salter A.H.   Large-scale databases in toxicogenomics Pharmacogenomics 2005 6 749 754 16207151 
22 Wheeler D.L.  Barrett T.  Benson D.A.  Bryant S.H.  Canese K.  Chetvernin V.  Church D.M.  DiCuccio M.  Edgar R.  Federhen S.    Database resources of the national center for biotechnology information Nucleic Acids Res. 2006 34 D173 D180 16381840 
23 Hosford D.A.  Lai E.H.  Riley J.H.  Xu C.F.  Danoff T.M.  Roses A.D.   Pharmacogenetics to predict drug-related adverse events Toxicol. Pathol. 2004 32 9 12 15209398 
24 Ranganathan P.  Eisen S.  Yokoyama W.M.  McLeod H.L.   Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann. Rheum. Dis. 2003 62 4 9 12480661 
25 Hiratsuka M.  Kishikawa Y.  Takekuma Y.  Matsuura M.  Narahara K.  Inoue T.  Hamdy S.I.  Endo N.  Goto J.  Mizugaki M.   Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients Drug Metab. Pharmacokinet. 2002 17 357 362 15618686 
26 Yoshida K.  Takahashi H.  Higuchi H.  Kamata M.  Ito K.  Sato K.  Naito S.  Shimizu T.  Itoh K.  Inoue K.    Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms Am. J. Psychiatr. 2004 161 1575 1580 15337646 
27 Carlini L.E.  Meropol N.J.  Bever J.  Andria M.L.  Hill T.  Gold P.  Rogatko A.  Wang H.  Blanchard R.L.   UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan Clin. Cancer Res. 2005 11 1226 1236 15709193 
28 Anttila S.  Illi A.  Kampman O.  Mattila K.M.  Lehtimaki T.  Leinonen E.   Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics Pharmacogenetics 2004 14 303 307 15115916 
29 Kajinami K.  Brousseau M.E.  Ordovas J.M.  Schaefer E.J.   Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin Atherosclerosis 2004 175 287 293 15262185 
30 Zazzi M.  Romano L.  Venturi G.  Shafer R.W.  Reid C.  Dal Bello F.  Parolin C.  Palu G.  Valensin P.E.   Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype J. Antimicrob. Chemother. 2004 53 356 360 14688053 
31 Debouck C.  Metcalf B.   The impact of genomics on drug discovery Annu. Rev. Pharmacol. Toxicol. 2000 40 193 207 10836133 
32 Eddershaw P.J.  Beresford A.P.  Bayliss M.K.   ADME/PK as part of a rational approach to drug discovery Drug Discov. Today 2000 5 409 414 10931658 
33 Li A.P.   Screening for human ADME/Tox drug properties in drug discovery Drug Discov. Today 2001 6 357 366 11267922 
34 Lin J.H.  Lu A.Y.   Role of pharmacokinetics and metabolism in drug discovery and development Pharmacol. Rev. 1997 49 403 449 9443165 
35 Mobley C.  Hochhaus G.   Methods used to assess pulmonary deposition and absorption of drugs Drug Discov. Today 2001 6 367 375 11267923 
36 Dove A.   Proteomics: translating genomics into products? Nat. Biotechnol. 1999 17 233 236 10096288 
37 Scharpe S.  De Meester I.   Peptide truncation by dipeptidyl peptidase IV: a new pathway for drug discovery? Verh. K. Acad. Geneeskd Belg. 2001 63 5 32 discussion 32–33 11284388 
38 Basile V.S.  Ozdemir V.  Masellis M.  Walker M.L.  Meltzer H.Y.  Lieberman J.A.  Potkin S.G.  Alva G.  Kalow W.  Macciardi F.M.    A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia Mol. Psychiatr. 2000 5 410 417 
39 Kapitany T.  Meszaros K.  Lenzinger E.  Schindler S.D.  Barnas C.  Fuchs K.  Sieghart W.  Aschauer H.N.  Kasper S.   Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia Schizophr. Res. 1998 32 101 106 9713905 
40 Serretti A.  Zanardi R.  Rossini D.  Cusin C.  Lilli R.  Smeraldi E.   Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity Mol. Psychiatr. 2001 6 586 592 
41 Smits K.M.  Smits L.J.  Schouten J.S.  Stelma F.F.  Nelemans P.  Prins M.H.   Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review Mol. Psychiatr. 2004 9 433 441 
42 Rau T.  Wohlleben G.  Wuttke H.  Thuerauf N.  Lunkenheimer J.  Lanczik M.  Eschenhagen T.   CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants—a pilot study Clin. Pharmacol. Ther. 2004 75 386 393 15116051 
43 Siddiqui A.  Kerb R.  Weale M.E.  Brinkmann U.  Smith A.  Goldstein D.B.  Wood N.W.  Sisodiya S.M.   Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1 N. Engl. J. Med. 2003 348 1442 1448 12686700 
44 Saitoh A.  Singh K.K.  Powell C.A.  Fenton T.  Fletcher C.V.  Brundage R.  Starr S.  Spector S.A.   An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children AIDS 2005 19 371 380 15750390

